HARRIS & HARRIS GROUP INC /NY/ Form 10-Q August 10, 2015
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
Form 10-Q
x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2015
" TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission file number: 0-11576
HARRIS & HARRIS GROUP, INC.
(Exact Name of Registrant as Specified in Its Charter)
New York 13-3119827 (State or Other Jurisdiction of (I.R.S. Employer Identification No.) Incorporation or Organization)

1450 Broadway, New York, New York 10018 (Address of Principal Executive Offices) (Zip Code)

(212) 582-0900

(Registrant's Telephone Number, Including Area Code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x No "

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes "No "

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer " Accelerated filer x
Non-accelerated filer " Smaller reporting company "
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes "No x

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Class Outstanding at August 10, 2015 Common Stock, \$0.01 par value per share 31,321,685 shares

Harris & Harris Group, Inc.

Form 10-Q, June 30, 2015

	Page Number
PART I. FINANCIAL INFORMATION	
Item 1. Consolidated Financial Statements	1
Consolidated Statements of Assets and Liabilities	2
Consolidated Statements of Operations	3
Consolidated Statements of Comprehensive Loss	4
Consolidated Statements of Cash Flows	5
Consolidated Statements of Changes in Net Assets	6
Consolidated Schedule of Investments	7
Notes to Consolidated Financial Statements	39
Financial Highlights	65
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	66
Cautionary Statement Regarding Forward-Looking Statements	66
Background	67
Overview	67
Realize	70
<u>Invest</u>	76
Current Business Environment	79
<u>Valuation of Investments</u>	80
Results of Operations	84
Financial Condition	94

Cash Flow	95
Liquidity and Capital Resources	96
Borrowings	97
Contractual Obligations	98
Critical Accounting Policies	98
Recent Developments – Portfolio Companies	102
Recent Developments – Other	102
Item 3. Quantitative and Qualitative Disclosures About Market Risk	103
Item 4. Controls and Procedures	105
PART II. OTHER INFORMATION	
Item 1A. Risk Factors	106
Item 6. Exhibits	106
<u>Signatures</u>	107
Exhibit Index	108
Financial Statements Schedule 12-14	i-v

PART I. FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements

In the opinion of management, these financial statements reflect all adjustments, consisting of valuation adjustments and normal recurring accruals, necessary for a fair statement of our financial position, results of operations and cash flows for such periods.

Harris & Harris Group, Inc.® (the "Company," "us," "our" and "we"), is an internally managed, non-diversified management investment company that has elected to operate as a business development company ("BDC") under the Investment Company Act of 1940 (the "1940 Act"). Certain information and disclosures normally included in the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America ("GAAP") have been condensed or omitted as permitted by Regulation S-X and Regulation S-K. Accordingly, they do not include all information and disclosures necessary for a fair presentation of our financial position, results of operations and cash flows in conformity with GAAP. The results of operations for any interim period are not necessarily indicative of the results for the full year. The accompanying consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2014.

CONSOLIDATED STATEMENTS OF ASSETS AND LIABILITIES

(Unaudited)

Net assets are comprised of:

	June 30, 2015	December 31, 2014
ASSETS		
Investments, in portfolio securities at value:		
Unaffiliated privately held companies	\$7,452,767	\$ 13,854,906
(cost: \$20,307,754 and \$22,304,047, respectively)	. , ,	, ,
Unaffiliated rights to milestone payments	3,181,183	3,193,865
(adjusted cost basis: \$2,387,278 and \$2,387,278, respectively)	, ,	, ,
Unaffiliated publicly traded securities	1,561,988	1,398,085
(cost: \$1,682,079 and \$1,741,128, respectively)	, ,	,,
Non-controlled affiliated privately held companies	58,952,248	58,470,864
(cost: \$64,678,768 and \$67,236,533, respectively)	,,	, ,
Non-controlled affiliated publicly traded companies	10,695,100	8,384,641
(cost: \$11,683,371 and \$5,591,299, respectively)	10,000,100	0,501,011
Controlled affiliated privately held companies	5,207,773	4,462,479
(cost: \$13,505,442 and \$13,111,030, respectively)	3,207,773	1,102,179
Equity method privately held companies	288,391	0
(adjusted cost basis: \$288,391 and \$0, respectively)	200,371	O
Total, investments in private portfolio companies, rights to milestone		
payments, public securities at value	\$87,339,450	\$ 89,764,840
(cost: \$114,533,083 and \$112,371,315, respectively)		
Cash	22,982,089	20,748,314
Funds held in escrow from sales of investments at value (Note 3)	372,835	306,802
Receivable from portfolio company	17,500	160,877
Interest receivable	72,826	62,482
Prepaid expenses	554,767	754,856
Other assets	417,265	296,690
Total assets	\$111,756,732	\$ 112,094,861
LIABILITIES & NET ASSETS		
Term loan credit facility (Note 5)	\$5,000,000	\$ 0
Post retirement plan liabilities (Note 8)	1,293,962	1,267,615
Accounts payable and accrued liabilities	674,840	841,915
Deferred rent	305,192	330,904
Total liabilities	\$7,273,994	\$ 2,440,434
Total natifices	Ψ 1,213,77	Ψ 2,440,434
Commitments and contingencies (Note 12)		
Net assets	\$104 482 738	\$ 109,654,427
Tive dissolu	ψ 101,102,730	Ψ 102,027,721

Preferred stock, \$0.10 par value,	\$0	\$ 0	
2,000,000 shares authorized; none issued	ΨΟ	ΨΟ	
Common stock, \$0.01 par value, 45,000,000 shares			
authorized at 6/30/15 and 12/31/14; 33,150,425 and	331,504	331,096	
33,109,583 issued at 6/30/15 and 12/31/14, respectively			
Additional paid in capital (Note 9)	215,435,591	215,051,662	
Accumulated net operating and realized loss	(81,298,904)	(80,434,528)
Accumulated unrealized depreciation of investments	(27,193,633)	(22,606,475)
Accumulated other comprehensive income (Note 8)	613,711	718,203	
Treasury stock, at cost (1,828,740 shares at 6/30/15 and 12/31/14)	(3,405,531)	(3,405,531)
Net assets	\$104,482,738	\$ 109,654,427	
Shares outstanding	31,321,685	31,280,843	
Net asset value per outstanding share	\$3.34	\$ 3.51	

The accompanying unaudited notes are an integral part of these consolidated financial statements.

CONSOLIDATED STATEMENTS OF OPERATIONS

	Three Months Ended June 30, 2015 2014		-	
Investment income:				
Interest from:				
Unaffiliated companies	\$9,533	\$ 36,447	\$20,776	\$86,682
Non-controlled affiliated companies	201,896	41,095	254,322	83,371
Controlled affiliated companies	47,207	36,607	91,633	71,333
Cash and U.S. Treasury securities and other	3,318	2,929	4,748	6,478
Fees for providing managerial assistance to portfolio companies	6,500	0	13,500	0
Yield-enhancing fees on debt securities	19,741	16,757	46,048	32,262
Total investment income	288,195	133,835	431,027	280,126
Expenses: Salaries, benefits and stock-based compensation (Note 9) Administration and operations Professional fees Rent Insurance expense Directors' fees and expenses Interest and other debt expenses Custody fees Depreciation Total expenses	977,689 134,860 314,785 67,758 73,724 68,901 208,026 15,704 12,055 1,873,502	1,247,426 206,960 385,352 80,065 84,007 93,131 94,276 14,228 13,245 2,218,690	2,056,178 236,094 887,019 135,464 141,335 188,525 351,746 31,616 24,702 4,052,679	2,659,786 337,440 597,223 148,091 167,940 186,408 187,996 29,019 26,450 4,340,353
Net operating loss	(1,585,307) (2,084,855) (3,621,652)	(4,060,227)
Net realized gain (loss): Realized gain (loss) from investments: Unaffiliated companies Non-Controlled affiliated companies Publicly traded companies Written call options Realized gain (loss) from investments	3,289,351 (98,644 41,411 0 3,232,118	3,946,838) 588,221 960,882 197,309 5,693,250	3,299,836 (392,430) 41,411 0 2,948,817	3,946,838 (6,711,063) 1,333,497 86,653 (1,344,075)
Income tax expense (Note 10) Net realized gain (loss) from investments	1,600 3,230,518	0 5,693,250	1,705 2,947,112	15,986 (1,360,061)

Edgar Filing: HARRIS & HARRIS GROUP INC /NY/ - Form 10-Q

Net (increase) decrease in unrealized						
depreciation on investments:						
Investments	(3,116,377)	796,969		(4,587,158)	3,183,622
Written call options	0		(77,309)	0	89,044
Net (increase) decrease in unrealized	(3,116,377)	719,660		(4,587,158)	3,272,666
depreciation on investments	(3,110,377	,	717,000		(4,507,150)	3,272,000
N. P. I. I. P. I. S.						
Net realized and unrealized gains	114,141		6,412,910		(1,640,046)	1,912,605
(loss) on investments						
Share of loss on equity method investment	(58,330	`	0		(189,836)	0
share of loss on equity method investment	(30,330	,	V		(10),030	O
Net (decrease) increase in net assets						
resulting from operations:						
Total	\$(1,529,496) :	\$4,328,055		\$(5,451,534)	\$(2,147,622)
Decrees the decree of Plant decreased in the second	¢ (0, 05		¢ Ω 1 4		¢ (O 17	Φ (O O 7
Per average basic and diluted outstanding share	\$ (0.05)	\$0.14		\$(0.17)	\$(0.07)
Average outstanding shares	31,285,894		31,201,574		31,283,382	31,199,518
Tivorage outstanding snares	51,205,074		31,201,377		31,203,302	31,177,310

The accompanying unaudited notes are an integral part of these consolidated financial statements.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(Unaudited)

	Three Months 2015	s E	nded June 30, 2014		Six Months l 2015		ded June 30, 2014	
Net (decrease) increase resulting from operations	\$ (1,529,496)	\$ 4,328,055		\$(5,451,534)	\$(2,147,622)
Other comprehensive (loss) income:								
Amortization of prior service cost	(52,246)	(52,246)	(104,492)	(104,492)
Other comprehensive loss	(52,246)	(52,246)	(104,492)	(104,492)
Comprehensive (loss) income	\$ (1,581,742)	\$ 4,275,809		\$(5,556,026)	\$(2,252,114)

The accompanying unaudited notes are an integral part of these consolidated financial statements.

CONSOLIDATED STATEMENTS OF CASH FLOWS

	Six Months Ended June 30, 2015	Six Months Ended June 30, 2014	
Cash flows (used in) provided by operating activities:	Φ (5.451.524) # (0.147.600	
Net (decrease) in net assets resulting from operations	\$ (5,451,534) \$ (2,147,622)
Adjustments to reconcile net (decrease) in net assets			
resulting from operations to net cash provided by			
(used in) operating activities:			
Net realized loss (gain) and change in unrealized	1,638,341	(1,928,591)
depreciation (appreciation) on investments			
Depreciation of fixed assets, amortization of prepaid assets and accretion of bridge note interest	(279,990) (140,878)
Share of loss on equity method investee	189,836	0	
Stock-based compensation expense	431,981	497,634	
Amortization of prior service cost	(104,492		`
Purchase of U.S. government securities	0	(19,999,044)
Sale of U.S. government securities	0	38,998,052	,
Purchase of equity method investment	(262,215) 0	
Purchase of affiliated portfolio companies	(4,275,915	, (0 = 1 1 0 0 0)
Purchase of unaffiliated portfolio companies	(509,824) (240,500	<i>,</i>)
Payments received on debt investments	186,109	224,711	,
Proceeds from sale of investments and conversion of bridge notes	5,698,094	9,766,197	
Proceeds from call option premiums	0	338,229	
Payments for put and call option purchases	0)
			•
Changes in assets and liabilities:			
Receivable from sales of investments	0	448,886	
Receivable from portfolio company	143,377	(325)
Interest receivable	(10,344) 1,202	
Prepaid expenses	200,089	240,034	
Other assets	(138,848) (2,209)
Post retirement plan liabilities	26,347	32,409	
Accounts payable and accrued liabilities	(167,075) 179,145	
Deferred rent	(25,712) (22,293)
Net cash (used in) provided by operating activities	(2,711,775) 16,207,714	
Cash flows from investing activities:			
Purchase of fixed assets	(6,806) (1,066)
Net cash used in investing activities	(6,806)

Cash flows from financing activities:			
Proceeds from drawdown of loan facility	5,000,000	0	
Payment of withholdings related to net settlement of restricted stock	(47,644) (68,872)
Net cash provided by (used in) financing activities	4,952,356	(68,872)
Net increase in cash	\$ 2,233,775	\$ 16,137,776	
Cash at beginning of the period	20,748,314	8,538,548	
Cash at end of the period	\$ 22,982,089	\$ 24,676,324	
Supplemental disclosures of cash flow information:			
Income taxes paid	\$ 1,705	\$ 15,986	

The accompanying unaudited notes are an integral part of these consolidated financial statements.

CONSOLIDATED STATEMENTS OF CHANGES IN NET ASSETS

	Six Months Ended June 30, 2015	Year Ended December 31, 2014		
Changes in net assets from operations:				
Net operating loss Net realized gain (loss) on investments	\$ (3,621,652 2,947,112)	\$ (7,901,727 (5,083,625)
Net (increase) in unrealized depreciation on investments	(4,587,158)	(576,186)
Net (decrease) in unrealized appreciation on written call options	0		(8,882)
Share of loss on equity method investment	(189,836)	0	
Net decrease in net assets resulting from operations	(5,451,534)	(13,570,420)
Changes in net assets from capital stock transactions:				
Acquisition of vested restricted stock awards to pay required employee withholding tax	(47,644)	(124,751)
Stock-based compensation expense	431,981		857,006	
Net increase in net assets resulting from capital stock transactions	384,337		732,255	
Changes in net assets from accumulated other comprehensive (loss) income:				
Other comprehensive (loss)	(104,492)	(208,983)
Net (decrease) in net assets resulting from accumulated other comprehensive (loss) income	(104,492)	(208,983)
Net decrease in net assets	(5,171,689)	(13,047,148)
Net Assets:				
Beginning of the period	109,654,427		122,701,575	

End of the period

\$ 104,482,738

\$ 109,654,427

The accompanying unaudited notes are an integral part of these consolidated financial statements.

CONSOLIDATED SCHEDULE OF INVESTMENTS AS OF JUNE 30, 2015

	Method of Valuation (1)	Primary Industry (2)	Cost	Shares/ Principal	Val <u>ue</u>
Investments in Unaffiliated Companies (3) – 11.7% of net assets at value					
Private Placement Portfolio (Illiquid) (4) – 7.1% of net assets at value					
Bridgelux, Inc. (5)(8)(9)(10) Manufacturing high-power light emitting diodes (LEDs) and arrays		Energy			
Series B Convertible Preferred Stock Series C Convertible Preferred Stock Series D Convertible Preferred Stock Series E Convertible Preferred Stock Series E-1 Convertible Preferred Stock	(M) (M) (M) (M) (M)		\$1,000,000 1,352,196 1,371,622 672,599 386,073	1,861,504 2,130,699 999,999 440,334 399,579	\$259,311 535,508 738,068 608,448 401,208
Warrants for Series C Convertible Preferred Stock expiring 8/31/15 Warrants for Series D Convertible Preferred	(M) (M)		168,270 128,543	163,900 166,665	0
Stock expiring 8/31/15 Warrants for Series E Convertible Preferred Stock expiring 12/31/17 Warrants for Common Stock expiring 6/1/16 Warrants for Common Stock expiring 8/9/18	(M) (M) (M)		93,969 72,668 148,409	170,823 132,100 171,183	0 0 0
Warrants for Common Stock expiring 10/21/18	(M)		18,816 5,413,165	84,846	0 2,542,543
Cambrios Technologies Corporation (5)(8)(9) Developing nanowire-enabled electronic materials for the display industry		Electronics			
Series B Convertible Preferred Stock Series C Convertible Preferred Stock Series D Convertible Preferred Stock Series D-2 Convertible Preferred Stock Series D-4 Convertible Preferred Stock	(I) (I) (I) (I) (I)		1,294,025 1,300,000 515,756 92,400 216,168 3,418,349	1,294,025 1,300,000 515,756 92,400 216,168	47,659 47,879 368,541 33,322 77,955 575,356
Cobalt Technologies, Inc. (8)(9)(10)(11)		Energy			

Edgar Filing: HARRIS & HARRIS GROUP INC /NY/ - Form 10-Q

Developed processes for making bio-				
butanol through biomass fermentation				
Series C-1 Convertible Preferred Stock	(M)	749,998	352,112	0
Series D-1 Convertible Preferred Stock	(M)	122,070	48,828	0
Series E-1 Convertible Preferred Stock	(M)	114,938	46,089	0
Warrants for Series E-1 Pref. Stock expiring on 10/9/22	(I)	2,781	1,407	0
Warrants for Series E-1 Pref. Stock expiring on 3/11/23	(I)	5,355	2,707	0
		995,142		0

The accompanying unaudited notes are an integral part of these consolidated financial statements.

CONSOLIDATED SCHEDULE OF INVESTMENTS AS OF JUNE 30, 2015

	Method of Valuation (1)	Primary Industry (2)	Cost	Shares/ Principal	Value
Investments in Unaffiliated Companies (3) – 11.7% of net assets at value (Cont.)					
Private Placement Portfolio (Illiquid) (4) – 7.1% of net assets at value (Cont.)					
Magic Leap, Inc. (8)(9)(12) Developing novel human computing interfaces and software		Electronics			
Series B Convertible Preferred Stock	(I)		\$338,604	29,291	\$319,472
Mersana Therapeutics, Inc. (5)(8)(9) Developing antibody drug conjugates		Life Sciences			
for cancer therapy Series A-1 Convertible Preferred Stock Series B-1 Convertible Preferred Stock Common Stock	(I) (I) (I)		683,538 104,521 3,875,395 4,663,454	635,081 97,111 350,539	455,263 107,706 143,695 706,664
Nanosys, Inc. (5)(8) Developing inorganic nanowires and		Energy			
quantum dots for use in LED-backlit devices Series C Convertible Preferred Stock Series D Convertible Preferred Stock Series E Convertible Preferred Stock	(M) (M) (M)		1,500,000 3,000,003 496,573 4,996,576	803,428 1,016,950 433,688	491,935 1,674,974 664,176 2,831,085
Nano Terra, Inc. (5) Developing surface chemistry and nano-		Energy			
manufacturing solutions Senior secured debt, 12.0%, maturing on 12/1/15	(I)		163,857	\$199,259	198,420
Warrants for Common Stock expiring on 2/22/21	(1)		69,168	4,462	1,365

Warrants for Series A-3 Pref. Stock expiring on 11/15/22	(I)	35,403	47,508	63,826
		268,428		263,611

The accompanying unaudited notes are an integral part of these consolidated financial statements.

CONSOLIDATED SCHEDULE OF INVESTMENTS AS OF JUNE 30, 2015

	Method of Valuation (1)	Primary Industry (2)	Cost	Shares/ Principal	Value
Investments in Unaffiliated Companies (3) –					
11.7% of net assets at value (Cont.)					
Private Placement Portfolio (Illiquid) (4) –					
7.1% of net assets at value (Cont.)					
Phylagen, Inc. (5)(8)(13) Developing technology to improve human		Life Sciences			
health and productivity Secured Convertible Bridge Note, 5%, acquired 2/5/15 Secured Convertible Bridge Note, 5%, acquired 6/5/15	(M) (M)		\$204,000 10,036 214,036	\$200,000 \$10,000	\$204,000 10,036 214,036
Total Unaffiliated Private Placement Portfolio (c	cost: \$20,307,7:	54)			\$7,452,767
Rights to Milestone Payments (Illiquid) (6) – 3.1% of net assets at value					
Amgen, Inc. (8)(9) Rights to Milestone Payments from	(I)	Life Sciences	\$1.757.608	\$1,757,608	\$2,549,261
Acquisition of BioVex Group, Inc.	(1)		ψ 1,707,000	ψ 1,707,000	\$ 2,0 13, 2 01
Laird Technologies, Inc. (8)(9) Rights to Milestone Payments from Merger &		Energy			
Acquisition of Nextreme Thermal Solutions, Inc.					